Tech Company Inital Public Offerings
Poseida Therapeutics IPO
On 7/9/2020, Poseida Therapeutics completed its IPO
Transaction Overview
Company Name
Announced On
7/9/2020
Transaction Type
IPO
Amount
$224,000,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: for our ongoing clinical development of P-BCMA-101 for relapsed/refractory multiple myeloma, including clinical trial costs and manufacturing expenses; for our ongoing clinical development of P-PSMA-101 for mCRPC, including clinical trial costs and manufacturing expenses; for our planned clinical development of P-BCMA-ALLO1 for relapsed/refractory multiple myeloma, including clinical trial costs and manufacturing expenses; and the remainder for developing our gene therapy and other CAR-T preclinical product candidates and research programs, as well as for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
9390 Towne Centre Dr. 200
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Poseida Therapeutics (Nasdaq: PSTX) utilizes best-in-class, proprietary genome editing technologies to develop targeted, life-saving therapeutics in areas of high unmet medical need.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 7/9/2020: Quaestor venture capital transaction
Next: 7/9/2020: PrizePicks venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs